Phosphate: The new cholesterol? The role of the phosphate axis in non-uremic vascular disease

Atherosclerosis

Volumn 220, Issue 2, 2012, Pages 310-318

  Ellam, Timothy J ^a,b   Chico, Timothy J A ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Atherosclerosis; Endothelial dysfunction; Fibroblast growth factor 23; Mortality; Parathyroid hormone; Phosphate; Vitamin D

Indexed keywords

CALCITRIOL; CALCIUM; CALCIUM CARBONATE; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D;

ATHEROGENESIS; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DIET RESTRICTION; DIETARY INTAKE; DRUG EFFECT; ENDOTHELIUM; HUMAN; HYPERPHOSPHATEMIA; KIDNEY DISEASE; MORTALITY; NONHUMAN; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

ANIMALS; BLOOD VESSELS; BONE AND BONES; CALCIUM; CHELATING AGENTS; CHOLESTEROL; FIBROBLAST GROWTH FACTORS; HUMANS; PARATHYROID HORMONE; PHOSPHATES; PHOSPHORUS, DIETARY; SIGNAL TRANSDUCTION; VASCULAR DISEASES; VITAMIN D;

EID: 84855966142     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.09.002     Document Type: Review

References (73)

1. Tonelli M., Sacks F., Pfeffer M., Gao Z., Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005, 112:2627-2633.
2. Dhingra R., Sullivan L.M., Fox C.S., et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007, 167:879-885.
3. Foley R.N., Collins A.J., Herzog C.A., Ishani A., Kalra P.A. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 2009, 20:397-404.
4. Foley R.N., Collins A.J., Ishani A., Kalra P.A. Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2008, 156:556-563.
5. Chonchol M., Dale R., Schrier R.W., Estacio R. Serum phosphorus and cardiovascular mortality in type 2 diabetes. Am J Med 2009, 122:380-386.
6. Foley R.N., Collins A.J., Herzog C.A., Ishani A., Kalra P.A. Serum phosphate and left ventricular hypertrophy in young adults: the coronary artery risk development in young adults study. Kidney Blood Press Res 2009, 32:37-44.
7. Larsson T.E., Olauson H., Hagstrom E., et al. Conjoint effects of serum calcium and phosphate on risk of total, cardiovascular, and noncardiovascular mortality in the community. Arterioscler Thromb Vasc Biol 2010, 30:333-339.
8. Abramowitz M., Muntner P., Coco M., et al. Serum alkaline phosphatase and phosphate and risk of mortality and hospitalization. Clin J Am Soc Nephrol 2010, 5:1064-1071.
9. Kestenbaum B., Sampson J.N., Rudser K.D., et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005, 16:520-528.
10. Park W., Kim B.S., Lee J.E., et al. Serum phosphate levels and the risk of cardiovascular disease and metabolic syndrome: a double-edged sword. Diabetes Res Clin Pract 2009, 83:119-125.
11. Lippi G., Montagnana M., Salvagno G.L., Targher G., Guidi G.C. Relationship between serum phosphate and cardiovascular risk factors in a large cohort of adult outpatients. Diabetes Res Clin Pract 2009, 84:e3-e5.
12. Kestenbaum B.R., Adeney K.L., de Boer I.H., Ix J.H., Shlipak M.G., Siscovick D.S. Incidence and progression of coronary calcification in chronic kidney disease: the Multi-Ethnic Study of Atherosclerosis. Kidney Int 2009, 76:991-998.
13. de Boer I.H., Rue T.C., Kestenbaum B. Serum phosphorus concentrations in the third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2009, 53:399-407.
14. Narang R., Ridout D., Nonis C., Kooner J.S. Serum calcium, phosphorus and albumin levels in relation to the angiographic severity of coronary artery disease. Int J Cardiol 1997, 60:73-79.
15. Kalantar-Zadeh K., Gutekunst L., Mehrotra R., et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol 2010, 5:519-530.
16. Pediatric reference ranges 1999, AACC Press, Washington. S.J. Soldin (Ed.).
17. Portale A.A., Halloran B.P., Morris R.C. Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D. J Clin Invest 1987, 80:1147-1154.
18. Kestenbaum B., Glazer N.L., Kottgen A., et al. Common genetic variants associate with serum phosphorus concentration. J Am Soc Nephrol 2010, 21:1223-1232.
19. Meyers K.J., Mosley T.H., Fox E., et al. Genetic variations associated with echocardiographic left ventricular traits in hypertensive blacks. Hypertension 2007, 49:992-999.
20. Block G.A., Hulbert-Shearon T.E., Levin N.W., Port F.K. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998, 31:607-617.
21. Phan O., Ivanovski O., Nguyen-Khoa T., et al. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 2005, 112:2875-2882.
22. Phan O., Ivanovski O., Nikolov I.G., et al. Effect of oral calcium carbonate on aortic calcification in apolipoprotein E-deficient (apoE-/-) mice with chronic renal failure. Nephrol Dial Transplant 2008, 23:82-90.
23. Jono S., McKee M.D., Murry C.E., et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000, 87:E10-E17.
24. Ritz E., Wanner C. The challenge of sudden death in dialysis patients. Clin J Am Soc Nephrol 2008, 3:920-929.
25. Sutton-Tyrrell K., Najjar S.S., Boudreau R.M., et al. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 2005, 111:3384-3390.
26. Ferro C.J., Chue C.D., Steeds R.P., Townend J.N. Is lowering phosphate exposure the key to preventing arterial stiffening with age?. Heart 2009, 95:1770-1772.
27. Kendrick J., Ix J.H., Targher G., Smits G., Chonchol M. Relation of serum phosphorus levels to ankle brachial pressure index (from the Third National Health and Nutrition Examination Survey). Am J Cardiol 2010, 106:564-568.
28. Ix J.H., De Boer I.H., Peralta C.A., et al. Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol 2009, 4:609-615.
29. Nadra I., Mason J.C., Philippidis P., et al. Proinflammatory activation of macrophages by basic calcium phosphate crystals via protein kinase C and MAP kinase pathways: a vicious cycle of inflammation and arterial calcification?. Circ Res 2005, 96:1248-1256.
30. Ewence A.E., Bootman M., Roderick H.L., et al. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ Res 2008, 103:e28-e34.
31. Westenfeld R., Schafer C., Kruger T., et al. Fetuin-A protects against atherosclerotic calcification in CKD. J Am Soc Nephrol 2009, 20:1264-1274.
32. Yao Y., Bennett B.J., Wang X., et al. Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification. Circ Res 2010, 107:485-494.
33. Scatena M., Liaw L., Giachelli C.M. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007, 27:2302-2309.
34. Venuraju S.M., Yerramasu A., Corder R., Lahiri A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 2010, 55:2049-2061.
35. Ellam T., Wilkie M., Chamberlain J., et al. Dietary phosphate modulates atherogenesis and insulin resistance in apolipoprotein e knockout mice. Arterioscler Thromb Vasc Biol 2011, 31:1988-1990.
36. Kanbay M., Nicoleta M., Selcoki Y., et al. Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin J Am Soc Nephrol 2010, 5:1780-1786.
37. Shuto E., Taketani Y., Tanaka R., et al. Dietary phosphorus acutely impairs endothelial function. J Am Soc Nephrol 2009, 20:1504-1512.
38. Di Marco G.S., Hausberg M., Hillebrand U., et al. Increased inorganic phosphate induces human endothelial cell apoptosis in vitro. Am J Physiol Renal Physiol 2008, 294:F1381-F1387.
39. Jin H., Xu C.X., Lim H.T., et al. High dietary inorganic phosphate increases lung tumorigenesis and alters Akt signaling. Am J Respir Crit Care Med 2009, 179:59-68.
40. Camalier C.E., Young M.R., Bobe G., Perella C.M., Colburn N.H., Beck G.R. Elevated phosphate activates N-ras and promotes cell transformation and skin tumorigenesis. Cancer Prev Res (Phila, PA) 2010, 3:359-370.
41. Bose S., French S., Evans F.J., Joubert F., Balaban R.S. Metabolic network control of oxidative phosphorylation: multiple roles of inorganic phosphate. J Biol Chem 2003, 278:39155-39165.
42. Kuro-o M. A potential link between phosphate and aging-lessons from Klotho-deficient mice. Mech Ageing Dev 2010, 131:270-275.
43. Koobi P., Vehmas T.I., Jolma P., et al. High-calcium vs high-phosphate intake and small artery tone in advanced experimental renal insufficiency. Nephrol Dial Transplant 2006, 21:2754-2761.
44. Lau W.L., Festing M.H., Giachelli C.M. Phosphate and vascular calcification: emerging role of the sodium-dependent phosphate co-transporter PiT-1. Thromb Haemost 2010, 104:464-470.
45. Antoniucci D.M., Yamashita T., Portale A.A. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006, 91:3144-3149.
46. Seiler S., Reichart B., Roth D., Seibert E., Fliser D., Heine G.H. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010, 25:3983-3989.
47. Yilmaz M.I., Sonmez A., Saglam M., et al. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 2010, 78:679-685.
48. Parker B.D., Schurgers L.J., Brandenburg V.M., et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010, 152:640-648.
49. Mirza M.A., Larsson A., Lind L., Larsson T.E. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009, 205:385-390.
50. Isakova T., Xie H., Yang W., et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011, 305:2432-2439.
51. Ikushima M., Rakugi H., Ishikawa K., et al. Anti-apoptotic and anti-senescence effects of Klotho on vascular endothelial cells. Biochem Biophys Res Commun 2006, 339:827-832.
52. Liu P., Bai X., Wang H., Karaplis A., Goltzman D., Miao D. Hypophosphatemia-mediated hypotension in transgenic mice overexpressing human FGF-23. Am J Physiol Heart Circ Physiol 2009, 297:H1514-H1520.
53. Mirza M.A., Alsio J., Hammarstedt A., et al. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol 2010, 31:219-227.
54. Portale A.A., Halloran B.P., Morris R.C. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest 1989, 83:1494-1499.
55. Dobnig H., Pilz S., Scharnagl H., et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 2008, 168:1340-1349.
56. Takeda M., Yamashita T., Sasaki N., et al. Oral administration of an active form of vitamin D3 (calcitriol) decreases atherosclerosis in mice by inducing regulatory T cells and immature dendritic cells with tolerogenic functions. Arterioscler Thromb Vasc Biol 2010, 30:2495-2503.
57. Oh J., Weng S., Felton S.K., et al. 1,25(OH)2 vitamin d inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation 2009, 120:687-698.
58. Talmor Y., Golan E., Benchetrit S., et al. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol 2008, 294:F1059-F1064.
59. Artaza J.N., Mehrotra R., Norris K.C. Vitamin D and the cardiovascular system. Clin J Am Soc Nephrol 2009, 4:1515-1522.
60. Hagstrom E., Hellman P., Larsson T.E., et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009, 119:2765-2771.
61. Pilz S., Tomaschitz A., Drechsler C., et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J 2010, 31:1591-1598.
62. Fitzpatrick L.A., Bilezikian J.P., Silverberg S.J. Parathyroid hormone and the cardiovascular system. Curr Osteoporos Rep 2008, 6:77-83.
63. Rashid G., Bernheim J., Green J., Benchetrit S. Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. Am J Physiol Renal Physiol 2007, 292:F1215-F1218.
64. Kosch M., Hausberg M., Vormbrock K., et al. Impaired flow-mediated vasodilation of the brachial artery in patients with primary hyperparathyroidism improves after parathyroidectomy. Cardiovasc Res 2000, 47:813-818.
65. Perkovic V., Hewitson T.D., Kelynack K.J., Martic M., Tait M.G., Becker G.J. Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cells. Kidney Blood Press Res 2003, 26:27-33.
66. Cheng S.L., Shao J.S., Halstead L.R., Distelhorst K., Sierra O., Towler D.A. Activation of vascular smooth muscle parathyroid hormone receptor inhibits Wnt/beta-catenin signaling and aortic fibrosis in diabetic arteriosclerosis. Circ Res 2010, 107:271-282.
67. Cunningham J., Danese M., Olson K., Klassen P., Chertow G.M. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005, 68:1793-1800.
68. Raggi P., Chertow G.M., Torres P.U., et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011, 26:1327-1339.
69. Joki N., Nikolov I.G., Caudrillier A., Mentaverri R., Massy Z.A., Drueke T.B. Effects of calcimimetic on vascular calcification and atherosclerosis in uremic mice. Bone 2009, 45(Suppl. 1):S30-S34.
70. Leroux-Berger M., Queguiner I., Maciel T.T., Ho A., Relaix F., Kempf H. Pathological calcification of adult vascular smooth muscle cells differs upon their crest or mesodermal embryonic origin. J Bone Miner Res 2011, 26:1543-1553.
71. Chen N.X., O'Neill K.D., Duan D., Moe S.M. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002, 62:1724-1731.
72. Alonso A., Nettleton J.A., Ix J.H., et al. Dietary phosphorus, blood pressure, and incidence of hypertension in the atherosclerosis risk in communities study and the multi-ethnic study of atherosclerosis. Hypertension 2010, 55:776-784.
73. Bolland M.J., Grey A., Avenell A., Gamble G.D., Reid I.R. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011, 342:d2040.